Cargando…
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492973/ https://www.ncbi.nlm.nih.gov/pubmed/32983148 http://dx.doi.org/10.3389/fimmu.2020.02029 |
| _version_ | 1783582471893286912 |
|---|---|
| author | Soria-Juan, Bárbara Escacena, Natalia Capilla-González, Vivian Aguilera, Yolanda Llanos, Lucía Tejedo, Juan R. Bedoya, Francisco J. Juan, Verónica De la Cuesta, Antonio Ruiz-Salmerón, Rafael Andreu, Enrique Grochowicz, Lukas Prósper, Felipe Sánchez-Guijo, Fermín Lozano, Francisco S. Miralles, Manuel Del Río-Solá, Lourdes Castellanos, Gregorio Moraleda, José M. Sackstein, Robert García-Arranz, Mariano García-Olmo, Damián Martín, Franz Hmadcha, Abdelkrim Soria, Bernat |
| author_facet | Soria-Juan, Bárbara Escacena, Natalia Capilla-González, Vivian Aguilera, Yolanda Llanos, Lucía Tejedo, Juan R. Bedoya, Francisco J. Juan, Verónica De la Cuesta, Antonio Ruiz-Salmerón, Rafael Andreu, Enrique Grochowicz, Lukas Prósper, Felipe Sánchez-Guijo, Fermín Lozano, Francisco S. Miralles, Manuel Del Río-Solá, Lourdes Castellanos, Gregorio Moraleda, José M. Sackstein, Robert García-Arranz, Mariano García-Olmo, Damián Martín, Franz Hmadcha, Abdelkrim Soria, Bernat |
| author_sort | Soria-Juan, Bárbara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7492973 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74929732020-09-24 Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus Soria-Juan, Bárbara Escacena, Natalia Capilla-González, Vivian Aguilera, Yolanda Llanos, Lucía Tejedo, Juan R. Bedoya, Francisco J. Juan, Verónica De la Cuesta, Antonio Ruiz-Salmerón, Rafael Andreu, Enrique Grochowicz, Lukas Prósper, Felipe Sánchez-Guijo, Fermín Lozano, Francisco S. Miralles, Manuel Del Río-Solá, Lourdes Castellanos, Gregorio Moraleda, José M. Sackstein, Robert García-Arranz, Mariano García-Olmo, Damián Martín, Franz Hmadcha, Abdelkrim Soria, Bernat Front Immunol Immunology Frontiers Media S.A. 2020-09-02 /pmc/articles/PMC7492973/ /pubmed/32983148 http://dx.doi.org/10.3389/fimmu.2020.02029 Text en Copyright © 2020 Soria-Juan, Escacena, Capilla-González, Aguilera, Llanos, Tejedo, Bedoya, Juan, De la Cuesta, Ruiz-Salmerón, Andreu, Grochowicz, Prósper, Sánchez-Guijo, Lozano, Miralles, Del Río-Solá, Castellanos, Moraleda, Sackstein, García-Arranz, García-Olmo, Martín, Hmadcha, Soria and the Collaborative Working Group “Noma Project Team”. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Soria-Juan, Bárbara Escacena, Natalia Capilla-González, Vivian Aguilera, Yolanda Llanos, Lucía Tejedo, Juan R. Bedoya, Francisco J. Juan, Verónica De la Cuesta, Antonio Ruiz-Salmerón, Rafael Andreu, Enrique Grochowicz, Lukas Prósper, Felipe Sánchez-Guijo, Fermín Lozano, Francisco S. Miralles, Manuel Del Río-Solá, Lourdes Castellanos, Gregorio Moraleda, José M. Sackstein, Robert García-Arranz, Mariano García-Olmo, Damián Martín, Franz Hmadcha, Abdelkrim Soria, Bernat Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
| title | Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
| title_full | Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
| title_fullStr | Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
| title_full_unstemmed | Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
| title_short | Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
| title_sort | corrigendum: cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492973/ https://www.ncbi.nlm.nih.gov/pubmed/32983148 http://dx.doi.org/10.3389/fimmu.2020.02029 |
| work_keys_str_mv | AT soriajuanbarbara corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT escacenanatalia corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT capillagonzalezvivian corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT aguilerayolanda corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT llanoslucia corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT tejedojuanr corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT bedoyafranciscoj corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT juanveronica corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT delacuestaantonio corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT ruizsalmeronrafael corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT andreuenrique corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT grochowiczlukas corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT prosperfelipe corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT sanchezguijofermin corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT lozanofranciscos corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT mirallesmanuel corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT delriosolalourdes corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT castellanosgregorio corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT moraledajosem corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT sacksteinrobert corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT garciaarranzmariano corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT garciaolmodamian corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT martinfranz corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT hmadchaabdelkrim corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT soriabernat corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT corrigendumcosteffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus |